1,2-二氢-7-甲基-2-苯基喹啉 | 1018838-80-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1,2-二氢-7-甲基-2-苯基喹啉
• 英文名称: 1,2-dihydro-7-methyl-2-phenylquinoline
• 英文别名: 7-Methyl-2-phenyl-1,2-dihydroquinoline
• CAS: 1018838-80-6
• 化学式: C₁₆H₁₅N
• 分子量: 221.302
• InChiKey: XGTQOQRLLUWNRO-UHFFFAOYSA-N

物化性质

• 沸点：
  376.9±42.0 °C(Predicted)
• 密度：
  1.074±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.18
• 重原子数：
  17.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  12.03
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  1,2-二氢-7-甲基-2-苯基喹啉 在 sulfur 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以84%的产率得到7-甲基-2-苯基喹啉
  参考文献：
  名称：

  Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors

  摘要：

  A series of novel, potent quinolinyl-derived imidazo[1,5-a]pyrazine IGF-IR (IGF-1R) inhibitors most notably, cis-3-(3-azetidin-1-ylmethylcyclobutyl)-1-(2-plienylquinotin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine (AQIP)-is described. Synthetic details, structure-activity relationships, and in vitro biological activity are reported for the series. Key in vitro and in vivo biological results for AQIP are reported, including: inhibition of ligand-stimulated autophosphorylation of IGF-IR and downstream pathways in 3T3/huIGFIR cells; inhibition of proliferation and induction of DNA fragmentation in human tumor cell lines; a pharmacokinetic profile suitable for once-per-day oral dosing; antitumor activity in a 3T3/huIGFIR xenograft model; and effects on insulin and glucose levels. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.10.061
• 作为产物：
  描述：

  7-甲基喹啉 、 苯基锂 以 四氢呋喃 、 二丁醚 为溶剂， 反应 0.5h， 以100%的产率得到1,2-二氢-7-甲基-2-苯基喹啉
  参考文献：
  名称：

  Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors

  摘要：

  A series of novel, potent quinolinyl-derived imidazo[1,5-a]pyrazine IGF-IR (IGF-1R) inhibitors most notably, cis-3-(3-azetidin-1-ylmethylcyclobutyl)-1-(2-plienylquinotin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine (AQIP)-is described. Synthetic details, structure-activity relationships, and in vitro biological activity are reported for the series. Key in vitro and in vivo biological results for AQIP are reported, including: inhibition of ligand-stimulated autophosphorylation of IGF-IR and downstream pathways in 3T3/huIGFIR cells; inhibition of proliferation and induction of DNA fragmentation in human tumor cell lines; a pharmacokinetic profile suitable for once-per-day oral dosing; antitumor activity in a 3T3/huIGFIR xenograft model; and effects on insulin and glucose levels. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.10.061